Turn Therapeutics Inc.

NASDAQ:TTRX

Biotechnology

Healthcare
$8.89 -2.79%

-$0.17 today

Market cap
$271.79M
Beta
2.77
P/E (TTM)
-45.0
EPS (TTM)
-$0.13
52W Low $2.57High $26.50

Volume 0.05M

Average 0.04M

TTRX Deferred Revenue (Non-current)

Payments received for goods or services the company will deliver after more than one year.

Turn Therapeutics Inc.NASDAQ: TTRX

Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue (non-current) of $1.44M in Q1 FY2026

Q1 FY2026 deferred revenue (non-current) was $1.44M.

Context

  • Deferred revenue (non-current) amounted to 7.7% of total assets at the end of Q1 FY2026.
  • Deferred revenue (non-current) increased in 0 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.44M+0.0% QoQ
Last fiscal yearDec 2025
$1.44M+0.0% YoY
Deferred Revenue (Non-current) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+0.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue (Non-current) history

USD · from the balance sheet

Latest · FY2025
1.44M USD
Year-over-year change
+0.0%
2-year CAGR
+0.0%

Deferred Revenue (Non-current) vs competitors

How TTRX compares with its peers on the latest reported figures

  • TTRX's Mar 2026 deferred revenue (non-current) of $1.44M is the highest of the 9 companies compared; the peer median is $0.
  • Deferred revenue (non-current) amounts to 7.7% of total assets for TTRX, versus a peer median of 0.0%.
TTRX Competitors Peer median
Deferred Revenue (Non-current) for TTRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TTRXTurn Therapeutics Inc.Mar 2026$1.44M ——7.7%
AGENAgenus Inc.Mar 2026$1.14M +0.0%+0.0%0.6%
IRDOpus Genetics, Inc.Mar 2026$0 ——0.0%
GLSIGreenwich LifeSciences, Inc.Mar 2026$0 ——0.0%
IKTInhibikase Therapeutics, Inc.Mar 2026$0 ——0.0%
ANIXAnixa Biosciences, Inc.Apr 2026$0 ——0.0%
HURATuHURA Biosciences, Inc.Mar 2026$0 ——0.0%
SEERSeer, Inc.Mar 2026$0 ——0.0%
CGTXCognition Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding TTRX) $0+0.0%+0.0%0.0%

Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents1.18M872.6K5.08M
Short-term Investments000
Net Receivables000
Inventory000
Other Current Assets20.82K225.33K0
Total Current Assets1.2M1.1M5.2M
Property, Plant & Equipment (Net)33.22K120.45K0
Goodwill000
Intangible Assets769.94K821.93K922.17K
Long-term Investments000
Tax Assets000
Other Non-current Assets8.58K8.58K6.04M
Total Non-current Assets811.74K950.97K6.97M
Total Assets2.01M2.05M12.16M
Account Payables002.93M
Short-term Debt000
Tax Payables000
Deferred Revenue000
Other Current Liabilities464.62K667.27K3.03M
Total Current Liabilities489.78K707.93K6M
Long-term Debt000
Deferred Tax Liabilities000
Deferred Revenue (Non-current)1.44M1.44M1.44M
Other Non-current Liabilities000
Total Non-current Liabilities1.44M1.52M1.47M
Total Liabilities1.93M2.23M7.48M
Common Stock1.32K1.34K2.94K
Retained Earnings(17.43M)(19.2M)(22.39M)
Accumulated OCI000
Other Stockholders Equity00(1.07M)
Minority Interest000
Total Equity85.77K(177.43K)4.69M
Total Debt25.16K121.04K80.38K
Net Debt(1.16M)(751.56K)(5M)

Turn Therapeutics Inc.

NASDAQ:TTRX

Intrinsic Alpha fair value

Locked

Current Price

$8.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.